Drug Profile
Declopramide
Alternative Names: IMO-B project; OXI 104Latest Information Update: 26 May 2003
Price :
$50
*
At a glance
- Originator OXiGENE
- Developer Active Biotech; Genzyme Oncology; Harvard Medical School; OXiGENE; University of Texas System
- Class Benzamides; Chemosensitisers; Small molecules
- Mechanism of Action DNA repair enzyme inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Cancer; Colorectal cancer; Inflammatory bowel diseases; Solid tumours
Most Recent Events
- 15 May 2003 Discontinued - Preclinical for Inflammatory bowel disease in Sweden (PO)
- 07 May 2002 Declopramide has been licensed to Active Biotech AB for World-wide rights
- 30 Apr 2002 Preclinical trials in Inflammatory bowel disease in Sweden (PO)